XML 127 R72.htm IDEA: XBRL DOCUMENT
v3.26.1

Commitments and Contingencies - Collaboration Agreements (FY) (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Feb. 29, 2020 | Mar. 31, 2026 | Dec. 31, 2025
Commitments and Contingencies |  |  |
Non - Refundable aggregate fees payable |  | $ 1,000 | $ 1,000
Non - Refundable upfront fees payable |  | 500 | 500
Non - Refundable fees payable |  | 500 | 500
Divestiture fee due to Catalent |  | 924 | 924
Amount of loss contingency |  | $ 0 | $ 0
Common stock | 150,000 |  |
Loss contingency, shares agreed by defendant | 33,836 | 1,692 | 1,692
Target annual bonus |  | 150.00% | 150.00%
Amended and restated agreement |  |  |
Commitments and Contingencies |  |  |
Amount payable per product candidate for rare, monogenic disorders |  | $ 16,500 | $ 16,500
Sales milestone payments |  | 55,000 | 55,000
Gemma License Agreement |  |  |
Commitments and Contingencies |  |  |
Amount payable per product candidate for rare, monogenic disorders |  | 16,500 | 16,500
Amount payable per product candidate upon achievement of specific development milestone |  | 39,000 | 39,000
Sales milestone payments |  | $ 55,000 | $ 55,000

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | pasg_AccruedDivestitureFeesCurrent
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement. + References No definition available. + Details
Name: | pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement. + References No definition available. + Details
Name: | pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of payable on sales milestone payment on collaboration and license agreement. + References No definition available. + Details
Name: | pasg_CollaborationAgreementSalesMilestonePaymentsPayable
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares agreed to be issued by defendant and subject to reverse stock split. + References No definition available. + Details
Name: | pasg_LossContingencySharesAgreedByDefendant
Namespace Prefix: | pasg_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of aggregate non-refundable fees payable per product indication. + References No definition available. + Details
Name: | pasg_NonRefundableAggregateFeesPayablePerProductIndication
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of upfront fees payable per product indication upon developmental milestone. + References No definition available. + Details
Name: | pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of upfront fees payable per product indication. + References No definition available. + Details
Name: | pasg_NonRefundableUpfrontFeesPayablePerProductIndication
Namespace Prefix: | pasg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the percentage of target annual bonus amounts. + References No definition available. + Details
Name: | pasg_PercentageOfTargetAnnualBonusAmounts
Namespace Prefix: | pasg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of stock issued during period for settlement of litigation. + References No definition available. + Details
Name: | pasg_StockIssuedDuringPeriodSettlementOfLitigation
Namespace Prefix: | pasg_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |